{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T20:47:42Z","timestamp":1747342062250,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Italian Diabetes Society"},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim\/hypothesis<\/jats:title>\n                <jats:p>We examined whether prediction of long-term kidney outcomes in individuals with type 2 diabetes can be improved by measuring circulating levels of haematopoietic stem\/progenitor cells (HSPCs), which are reduced in diabetes and are associated with cardiovascular risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included individuals with type 2 diabetes who had a baseline determination of circulating HSPCs in 2004\u20132019 at the diabetes centre of the University Hospital of Padua and divided them into two groups based on their median value per ml of blood. We collected updated data on eGFR and albuminuria up to December 2022. The primary endpoint was a composite of new-onset macroalbuminuria, sustained \u226540% eGFR decline, end-stage kidney disease or death from any cause. The analyses were adjusted for known predictors of kidney disease in the population with diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analysed 342 participants (67.8% men) with a mean age of 65.6 years. Those with low HSPC counts (<jats:italic>n<\/jats:italic>=171) were significantly older and had a greater prevalence of hypertension, heart failure and nephropathy (45.0% vs 33.9%; <jats:italic>p<\/jats:italic>=0.036), as evidenced by lower eGFR and higher albuminuria at baseline. During a median follow-up of 6.7 years, participants with high vs low HSPC counts had lower rates of the composite kidney outcome (adjusted HR 0.69 [95% CI 0.49, 0.97]), slower decline in eGFR and a similar increase in albuminuria. Adding the HSPC information to the risk score of the CKD Prognosis Consortium significantly improved discrimination of individuals with future adverse kidney outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions\/interpretation<\/jats:title>\n                <jats:p>HSPC levels predict worsening of kidney function and improve the identification of individuals with type 2 diabetes and adverse kidney outcomes over and beyond a clinical risk score.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00125-023-06002-6","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:01:56Z","timestamp":1694750516000},"page":"2346-2355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem\/progenitor cells"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6770-2723","authenticated-orcid":false,"given":"Benedetta Maria","family":"Bonora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6864-0547","authenticated-orcid":false,"given":"Mario Luca","family":"Morieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marella","family":"Marassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Cappellari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Avogaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-2097","authenticated-orcid":false,"given":"Gian Paolo","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"6002_CR1","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1001\/jama.2019.3471","volume":"321","author":"EW Gregg","year":"2019","unstructured":"Gregg EW, Hora I, Benoit SR (2019) Resurgence in diabetes-related complications. JAMA 321:1867\u20131868. https:\/\/doi.org\/10.1001\/jama.2019.3471","journal-title":"JAMA"},{"key":"6002_CR2","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","volume":"370","author":"EW Gregg","year":"2014","unstructured":"Gregg EW, Li Y, Wang J et al (2014) Changes in diabetes-related complications in the United States, 1990\u20132010. N Engl J Med 370:1514\u20131523. https:\/\/doi.org\/10.1056\/NEJMoa1310799","journal-title":"N Engl J Med"},{"key":"6002_CR3","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1097\/HJH.0b013e3283495cd6","volume":"29","author":"G Penno","year":"2011","unstructured":"Penno G, Solini A, Bonora E et al (2011) Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 29:1802\u20131809. https:\/\/doi.org\/10.1097\/HJH.0b013e3283495cd6","journal-title":"J Hypertens"},{"key":"6002_CR4","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00125-018-4691-2","volume":"61","author":"G Penno","year":"2018","unstructured":"Penno G, Solini A, Orsi E et al (2018) Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study. Diabetologia 61:2277\u20132289. https:\/\/doi.org\/10.1007\/s00125-018-4691-2","journal-title":"Diabetologia"},{"key":"6002_CR5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7:845\u2013854. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6002_CR6","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1172\/JCI72271","volume":"124","author":"K Reidy","year":"2014","unstructured":"Reidy K, Kang HM, Hostetter T, Susztak K (2014) Molecular mechanisms of diabetic kidney disease. J Clin Invest 124:2333\u20132340. https:\/\/doi.org\/10.1172\/JCI72271","journal-title":"J Clin Invest"},{"key":"6002_CR7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2337\/dc09-1999","volume":"33","author":"GP Fadini","year":"2010","unstructured":"Fadini GP, Boscaro E, de Kreutzenberg S et al (2010) Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 33:1097\u20131102. https:\/\/doi.org\/10.2337\/dc09-1999","journal-title":"Diabetes Care"},{"key":"6002_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/stmcls\/sxac035","volume":"40","author":"GP Fadini","year":"2022","unstructured":"Fadini GP, Albiero M (2022) Impaired hematopoietic stem\/progenitor cell traffic and multi-organ damage in diabetes. Stem Cells 40:716\u2013723. https:\/\/doi.org\/10.1093\/stmcls\/sxac035","journal-title":"Stem Cells"},{"key":"6002_CR9","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/eurheartj\/ehl198","volume":"27","author":"GP Fadini","year":"2006","unstructured":"Fadini GP, de Kreutzenberg SV, Coracina A et al (2006) Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J 27:2247\u20132255. https:\/\/doi.org\/10.1093\/eurheartj\/ehl198","journal-title":"Eur Heart J"},{"key":"6002_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2337\/dc16-1755","volume":"40","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Rigato M, Cappellari R, Bonora BM, Avogaro A (2017) Long-term prediction of cardiovascular outcomes by circulating CD34+ and CD34+CD133+ stem cells in patients with type 2 diabetes. Diabetes Care 40:125\u2013131. https:\/\/doi.org\/10.2337\/dc16-1755","journal-title":"Diabetes Care"},{"key":"6002_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.atherosclerosis.2009.03.040","volume":"207","author":"GP Fadini","year":"2009","unstructured":"Fadini GP, de Kreutzenberg S, Agostini C et al (2009) Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis 207:213\u2013219. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.03.040","journal-title":"Atherosclerosis"},{"key":"6002_CR12","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1161\/CIRCRESAHA.116.308366","volume":"118","author":"M Rigato","year":"2016","unstructured":"Rigato M, Avogaro A, Fadini GP (2016) Levels of circulating progenitor cells, cardiovascular outcomes and death: a meta-analysis of prospective observational studies. Circ Res 118:1930\u20131939. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308366","journal-title":"Circ Res"},{"key":"6002_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1056\/NEJMoa022287","volume":"348","author":"JM Hill","year":"2003","unstructured":"Hill JM, Zalos G, Halcox JP et al (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593\u2013600. https:\/\/doi.org\/10.1056\/NEJMoa022287","journal-title":"N Engl J Med"},{"key":"6002_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1056\/NEJMoa043814","volume":"353","author":"N Werner","year":"2005","unstructured":"Werner N, Kosiol S, Schiegl T et al (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999\u20131007. https:\/\/doi.org\/10.1056\/NEJMoa043814","journal-title":"N Engl J Med"},{"key":"6002_CR15","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1210\/jc.2015-1687","volume":"100","author":"M Rigato","year":"2015","unstructured":"Rigato M, Bittante C, Albiero M, Avogaro A, Fadini GP (2015) Circulating progenitor cell count predicts microvascular outcomes in type 2 diabetic patients. J Clin Endocrinol Metab 100:2666\u20132672. https:\/\/doi.org\/10.1210\/jc.2015-1687","journal-title":"J Clin Endocrinol Metab"},{"key":"6002_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"key":"6002_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394:131\u2013138. https:\/\/doi.org\/10.1016\/S0140-6736(19)31150-X","journal-title":"Lancet"},{"key":"6002_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9:653\u2013662. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6002_CR19","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2337\/dc22-0698","volume":"45","author":"ME Grams","year":"2022","unstructured":"Grams ME, Brunskill NJ, Ballew SH et al (2022) Development and validation of prediction models of adverse kidney outcomes in the population with and without diabetes. Diabetes Care 45:2055\u20132063. https:\/\/doi.org\/10.2337\/dc22-0698","journal-title":"Diabetes Care"},{"key":"6002_CR20","doi-asserted-by":"publisher","unstructured":"Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157\u2013172; discussion 207\u2013112 https:\/\/doi.org\/10.1002\/sim.3106","DOI":"10.1002\/sim.3106"},{"key":"6002_CR21","unstructured":"Kennedy KF, Pencina M (2010) A SAS\u00ae macro to compute added predictive ability of new markers predicting a dichotomous outcome. 2010 NCSU. Available from http:\/\/analytics.ncsu.edu\/sesug\/2010\/SDA07.Kennedy.pdf. Accessed 15 Mar 2023"},{"key":"6002_CR22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1464-5491.2010.03055.x","volume":"27","author":"A Nicolucci","year":"2010","unstructured":"Nicolucci A, Rossi MC, Arcangeli A et al (2010) Four-year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics: the AMD-Annals initiative. Diabet Med 27:1041\u20131048. https:\/\/doi.org\/10.1111\/j.1464-5491.2010.03055.x","journal-title":"Diabet Med"},{"key":"6002_CR23","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.2337\/db19-0640","volume":"69","author":"S Tedesco","year":"2020","unstructured":"Tedesco S, Ciciliot S, Menegazzo L et al (2020) Pharmacologic PPAR-gamma activation reprograms bone marrow macrophages and partially rescues HSPC mobilization in human and murine diabetes. Diabetes 69:1562\u20131572. https:\/\/doi.org\/10.2337\/db19-0640","journal-title":"Diabetes"},{"key":"6002_CR24","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1111\/j.1523-1755.2005.00291.x","volume":"67","author":"K Ikarashi","year":"2005","unstructured":"Ikarashi K, Li B, Suwa M et al (2005) Bone marrow cells contribute to regeneration of damaged glomerular endothelial cells. Kidney Int 67:1925\u20131933. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00291.x","journal-title":"Kidney Int"},{"key":"6002_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/path.976","volume":"195","author":"R Poulsom","year":"2001","unstructured":"Poulsom R, Forbes SJ, Hodivala-Dilke K et al (2001) Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol 195:229\u2013235. https:\/\/doi.org\/10.1002\/path.976","journal-title":"J Pathol"},{"key":"6002_CR26","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.2527\/1991.6973005x","volume":"69","author":"Z Zhang","year":"1991","unstructured":"Zhang Z, Paria BC, Davis DL (1991) Pig endometrial cells in primary culture: morphology, secretion of prostaglandins and proteins, and effects of pregnancy. J Anim Sci 69:3005\u20133015. https:\/\/doi.org\/10.2527\/1991.6973005x","journal-title":"J Anim Sci"},{"key":"6002_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41371-018-0145-z","volume":"33","author":"MW Skrzypkowska","year":"2019","unstructured":"Skrzypkowska MW, Gutknecht PG, Ryba-Stanislawowska ME, Slominski B, Siebert J, Mysliwska JM (2019) CD34+ and CD34+VEGFR2+ cells in poorly controlled hypertensive patients. J Hum Hypertens 33:863\u2013872. https:\/\/doi.org\/10.1038\/s41371-018-0145-z","journal-title":"J Hum Hypertens"},{"key":"6002_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.15171\/jcvtr.2014.004","volume":"6","author":"AE Berezin","year":"2014","unstructured":"Berezin AE, Kremzer AA, Samura TA, Berezina TA, Martovitskaya YV (2014) Serum uric acid predicts declining of circulating proangiogenic mononuclear progenitor cells in chronic heart failure patients. J Cardiovasc Thorac Res 6:153\u2013162. https:\/\/doi.org\/10.15171\/jcvtr.2014.004","journal-title":"J Cardiovasc Thorac Res"},{"key":"6002_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1161\/ATVBAHA.109.200154","volume":"30","author":"A Oikawa","year":"2010","unstructured":"Oikawa A, Siragusa M, Quaini F et al (2010) Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol 30:498\u2013508. https:\/\/doi.org\/10.1161\/ATVBAHA.109.200154","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6002_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1161\/ATVBAHA.112.300424","volume":"33","author":"G Mangialardi","year":"2013","unstructured":"Mangialardi G, Katare R, Oikawa A et al (2013) Diabetes causes bone marrow endothelial barrier dysfunction by activation of the RhoA-Rho-associated kinase signaling pathway. Arterioscler Thromb Vasc Biol 33:555\u2013564. https:\/\/doi.org\/10.1161\/ATVBAHA.112.300424","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6002_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature17624","volume":"532","author":"T Itkin","year":"2016","unstructured":"Itkin T, Gur-Cohen S, Spencer JA et al (2016) Distinct bone marrow blood vessels differentially regulate haematopoiesis. Nature 532:323\u2013328. https:\/\/doi.org\/10.1038\/nature17624","journal-title":"Nature"},{"key":"6002_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/s0008-6363(96)00272-6","volume":"34","author":"CD Stehouwer","year":"1997","unstructured":"Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW (1997) Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 34:55\u201368. https:\/\/doi.org\/10.1016\/s0008-6363(96)00272-6","journal-title":"Cardiovasc Res"},{"key":"6002_CR33","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1007\/s12325-021-01777-9","volume":"38","author":"F Rodriguez","year":"2021","unstructured":"Rodriguez F, Lee DJ, Gad SS et al (2021) Real-world diagnosis and treatment of diabetic kidney disease. Adv Ther 38:4425\u20134441. https:\/\/doi.org\/10.1007\/s12325-021-01777-9","journal-title":"Adv Ther"},{"key":"6002_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12882-019-1551-3","volume":"20","author":"CJ Diamantidis","year":"2019","unstructured":"Diamantidis CJ, Hale SL, Wang V, Smith VA, Scholle SH, Maciejewski ML (2019) Lab-based and diagnosis-based chronic kidney disease recognition and staging concordance. BMC Nephrol 20:357. https:\/\/doi.org\/10.1186\/s12882-019-1551-3","journal-title":"BMC Nephrol"},{"key":"6002_CR35","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/dom.15009","volume":"25","author":"BN Nguyen","year":"2023","unstructured":"Nguyen BN, Nguyen L, Mital S, Bugden S, Nguyen HV (2023) Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 25:1614\u20131623. https:\/\/doi.org\/10.1111\/dom.15009","journal-title":"Diabetes Obes Metab"},{"key":"6002_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Karasik A, Thuresson M et al (2020) Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol 8:27\u201335. https:\/\/doi.org\/10.1016\/S2213-8587(19)30384-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6002_CR37","doi-asserted-by":"publisher","first-page":"684","DOI":"10.2337\/dc21-2196","volume":"45","author":"J Koska","year":"2022","unstructured":"Koska J, Gerstein HC, Beisswenger PJ, Reaven PD (2022) Advanced glycation end products predict loss of renal function and high-risk chronic kidney disease in type 2 diabetes. Diabetes Care 45:684\u2013691. https:\/\/doi.org\/10.2337\/dc21-2196","journal-title":"Diabetes Care"},{"key":"6002_CR38","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2337\/db20-1045","volume":"70","author":"M Albiero","year":"2021","unstructured":"Albiero M, Tedesco S, Amendolagine FI et al (2021) Inhibition of SGLT2 rescues bone marrow cell traffic for vascular repair: role of glucose control and ketogenesis. Diabetes 70:1767\u20131779. https:\/\/doi.org\/10.2337\/db20-1045","journal-title":"Diabetes"},{"key":"6002_CR39","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cmet.2019.08.015","volume":"30","author":"DA Hess","year":"2019","unstructured":"Hess DA, Terenzi DC, Trac JZ et al (2019) SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. Cell Metab 30:609\u2013613. https:\/\/doi.org\/10.1016\/j.cmet.2019.08.015","journal-title":"Cell Metab"},{"key":"6002_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12933-021-01235-4","volume":"20","author":"SR Nandula","year":"2021","unstructured":"Nandula SR, Kundu N, Awal HB et al (2021) Role of canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes. Cardiovasc Diabetol 20:44. https:\/\/doi.org\/10.1186\/s12933-021-01235-4","journal-title":"Cardiovasc Diabetol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-06002-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-023-06002-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-06002-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T12:02:05Z","timestamp":1699272125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-023-06002-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6002"],"URL":"https:\/\/doi.org\/10.1007\/s00125-023-06002-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"type":"print","value":"0012-186X"},{"type":"electronic","value":"1432-0428"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"23 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BMB received lecture or advisory board fees from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Mundipharma, Novartis, Novo Nordisk and Sanofi. MLM received lecture fees or advisory board fees from Eli Lilly, MSD, Novo Nordisk, SLA-Pharma and Servier. AA received research grants and lecture or advisory board fees from MSD, AstraZeneca, Novartis, Boehringer Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier and Takeda. GPF received grants, honoraria or lecture fees from Abbott, AstraZeneca, Boehringer, Lilly, MSD, Novo Nordisk, Sanofi, Servier and Takeda. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"BMB contributed to study design, data research, analysis and interpretation, and manuscript writing. MLM contributed to study design, data research, analysis and interpretation, and manuscript revision. MM and RC contributed to data research, analysis and interpretation, and manuscript revision. AA contributed to study design, data interpretation and manuscript revision. GPF contributed to study design, data research, analysis and interpretation, and manuscript writing. All authors approved the final version of the manuscript. GPF is the guarantor of this study and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}